Showing 20 of 37 recruiting trials for “B-cell non-Hodgkin lymphoma”
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
👨⚕️ Narendranath Epperla, MD, MS, Huntsman Cancer Institute/ University of Utah📍 1 site📅 Started Oct 2025View details ↗
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
👨⚕️ Mengyang Di, MD, PhD, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Sep 2025View details ↗
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
KSV01 Injection for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
👨⚕️ Alessandra Tucci, Dr.ssa, UO Ematologia, ASST Spedali Civili di Brescia, Piazzale Spedali Civili, 1, 25123 Brescia, Italia📍 20 sites📅 Started Apr 2025View details ↗
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
👨⚕️ Aibin Liang MD,Ph.D., Shanghai Tongji Hospital, Tongji University School of Medicine📍 1 site📅 Started Dec 2024View details ↗
Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
🏥 Second Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Dec 2024View details ↗
RecruitingNCT06497452 ↗
A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma
👨⚕️ Qingqing Cai, Ph D, Sun Yat-Sen University Cancer Center📍 1 site📅 Started Apr 2024View details ↗
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →